580.530USD+580.530After-hours 10/30, 20:00 (ET)
16.43BMarket Cap
37.93P/E TTM
Currency: USD Updated: 2025-10-29 Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Medpace Holdings Inc's Score
Score Analysis
Current score
Previous score
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Medpace Holdings Inc Highlights
StrengthsRisks
Financial Indicators
EPS

No Data
Total revenue

No Data
Medpace Holdings Inc Info
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Ticker SymbolMEDP
CompanyMedpace Holdings Inc
CEODr. August J. Troendle, M.D.
Websitehttps://investor.medpace.com/